Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Identifies Cancer Target Using In-house System

NEW YORK, Oct. 9 – Myriad Genetics of Salt Lake City said Tuesday it had discovered a drug target for treating cancer using its proteomics technology.

In a statement, Myriad said that the ProNet technology allowed the company to look at protein interactions involved in apoptosis and to apply the knowledge garnered to identifying a target for cancer.

“Pre-clinical studies have demonstrated strong anti-cancer activity without harming normal human cell survival,” the company said in a statement.

Last month the company said that using ProNet it had found a drug target for hepatitis C. Myriad has also used the technique in its efforts to find drug targets for HIV and hepatitis B.

ProNet uses yeast two-hybrid to identify protein-protein interactions and to find intracellular, secreted, and membrane proteins. Myriad said that its system has a false positive rate of less than one percent and higher throughput than other methods. 

Myriad, which is currently conducting tests on a prostate cancer drug and a colon cancer, said that it would now deploy its medicinal and organic chemistry capabilities to further develop anti-cancer compounds.  

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.